ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Novartis and Chong Kun Dang Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

NovartisChong Kun Dang Pharmaceutical
studies on the registry3,902299
open to participants now21214
phase 3 studies under way942
reach primary completion within a year1284
programswith a study of their own in two years77+7 named only18

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseNovartisChong Kun Dang Pharmaceutical
Phase 1

Novartis: 16 of its 77 programs at phase 1

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  2. HJB647phase 1
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1
  5. Actinium Ac 225-ETN029phase 1

and 11 more — sign in to see them all

21%

Chong Kun Dang Pharmaceutical: 13 of its 18 programs at phase 1

  1. CKD-383phase 1
  2. CKD-215phase 1
  3. CKD-512phase 1
  4. CKD-704phase 1
  5. CKD-706phase 1

and 8 more — sign in to see them all

72%
Phase 2

Novartis: 35 of its 77 programs at phase 2

  1. Lutetium-177phase 2
  2. rapcabtagene autoleucelphase 2
  3. DDY391phase 2
  4. arumakimigphase 2
  5. QCZ484phase 2

and 30 more — sign in to see them all

45%

Chong Kun Dang Pharmaceutical: 1 of its 18 programs at phase 2

  1. Anti-c-Met/MMAE Antibody-drug Conjugate CKD-703phase 2
6%
Phase 3

Novartis: 18 of its 77 programs at phase 3

  1. remibrutinibphase 3
  2. ianalumabphase 3
  3. iptacopanphase 3
  4. pelabresibphase 3
  5. pelacarsenphase 3

and 13 more — sign in to see them all

23%

Chong Kun Dang Pharmaceutical: 2 of its 18 programs at phase 3

  1. CKD-843phase 3
  2. lobeglitazonephase 3
11%
Approved, new studies

Novartis: 8 of its 77 programs at approved, new studies

  1. inclisiranapproved, new study
  2. Alpelisibapproved, new study
  3. asciminibapproved, new study
  4. secukinumabapproved, new study
  5. ruxolitinibapproved, new study

and 3 more — sign in to see them all

10%

Chong Kun Dang Pharmaceutical: 2 of its 18 programs at approved, new studies

  1. empagliflozinapproved, new study
  2. Everolimusapproved, new study
11%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Novartis27 readouts · 5 phase 3

Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. inclisiranapproved, new study · Nov 27 · NCT06501443

Novartis, Dec ’26: 5 programs whose next study reaches primary completion

  1. luxdegalutamidephase 2 · Dec 3 · NCT06991556
  2. HJB647phase 1 · Dec 8 · NCT07465653
  3. gallium 68 PSMA-11phase 2 · Dec 23 · NCT05849298
  4. iptacopanphase 3 · Dec 30 · NCT06388941
  5. Lutetium-177phase 2 · Dec 30 · NCT05870579

Novartis, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. opnurasibphase 3 · Jan 25 · NCT04699188
  2. Alpelisibapproved, new study · Jan 28 · NCT05038735

Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. cipargaminphase 2 · Feb 4 · NCT07811908
  2. ganaplacidephase 3 · Feb 4 · NCT07811908
  3. remibrutinibphase 3 · Feb 22 · NCT06868212

Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PKN605phase 2 · Mar 1 · NCT07797322
  2. EDI-048phase 2 · Mar 23 · NCT07249463
  3. ianalumabphase 3 · Mar 26 · NCT05639114

Novartis, Apr ’27: 4 programs whose next study reaches primary completion

  1. arumakimigphase 2 · Apr 22 · NCT07203001
  2. DII235phase 2 · Apr 26 · NCT07235046
  3. QCZ484phase 2 · Apr 28 · NCT07610278
  4. delpacibart zotadirsenphase 3 · Apr 30 · NCT06244082

Novartis, May ’27: 3 programs whose next study reaches primary completion

  1. GIA632phase 2 · May 17 · NCT07220577
  2. luxdegalutamidephase 2 · May 25 · NCT05067140
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1 · May 31 · NCT05397496
·

Novartis, Jul ’27: 3 programs whose next study reaches primary completion

  1. EYU688phase 2 · Jul 22 · NCT06006559
  2. LXE408phase 2 · Jul 22 · NCT06632600
  3. GXV-813phase 2 · Jul 29 · NCT07467993

Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zigakibartphase 3 · Aug 10 · NCT05852938
  2. YMI024phase 2 · Aug 15 · NCT07830719

Novartis, Sep ’27: 1 program whose next study reaches primary completion

  1. asciminibapproved, new study · Sep 3 · NCT04925479
·
Chong Kun Dang Pharmaceutical5 readouts · 2 phase 3····

Chong Kun Dang Pharmaceutical, Mar ’27: 1 program whose next study reaches primary completion

  1. CKD-512phase 1 · Mar 0 · NCT07215637
··

Chong Kun Dang Pharmaceutical, Jun ’27: 2 programs whose next study reaches primary completion

  1. CKD-215phase 1 · Jun 0 · NCT07532148
  2. D215phase 1 · Jun 0 · NCT07532148
·

Chong Kun Dang Pharmaceutical, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. empagliflozinapproved, new study · Aug 0 · NCT07365358

Chong Kun Dang Pharmaceutical, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. CKD-843phase 3 · Sep 30 · NCT06916793
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Novartis

New programs 5

  • pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
  • DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
  • TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
  • XEP527phase 1 · first study · Oct 26 · Schizophrenia
  • YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease

Reached a new phase 1

Study stopped 6

  • remibrutinibphase 3 · terminated Nov 20“Sponsor decision based on pre-specified futility efficacy criteria being met.” · NCT06744920
  • Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
  • pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
  • opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
  • ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
  • pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306

Primary completion later 6

Chong Kun Dang Pharmaceutical

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 11 in all. A program counts in each condition its studies name most.

ConditionNovartisChong Kun Dang Pharmaceutical
Breast Neoplasmsboth · compare here

Novartis in Breast Neoplasms: 6 programs

  1. Gallium-68phase 3
  2. Lutetium-177phase 2
  3. GVV858phase 2
  4. ERW316phase 2
  5. IEV407phase 1

and 1 more — sign in to see them all

Their studies: Novartis’s studies of Breast Neoplasms in search

Chong Kun Dang Pharmaceutical in Breast Neoplasms: 1 program

  1. Everolimusapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Breast Neoplasms in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Novartis in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. opnurasibphase 3
  2. Lutetium-177phase 2
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1

Their studies: Novartis’s studies of Carcinoma, Non-Small-Cell Lung in search

Chong Kun Dang Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. Anti-c-Met/MMAE Antibody-drug Conjugate CKD-703phase 2
  2. Everolimusapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Dermatitis, Atopicboth · compare here

Novartis in Dermatitis, Atopic: 4 programs

  1. GIA632phase 2
  2. GHZ339phase 2
  3. DCY636phase 1
  4. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Dermatitis, Atopic in search

Chong Kun Dang Pharmaceutical in Dermatitis, Atopic: 1 program

  1. CKD-706phase 1

Their studies: Chong Kun Dang Pharmaceutical’s studies of Dermatitis, Atopic in search

Hypertensionboth · compare here

Novartis in Hypertension: 2 programs

  1. QCZ484phase 2
  2. HJB647phase 1

Their studies: Novartis’s studies of Hypertension in search

Chong Kun Dang Pharmaceutical in Hypertension: 1 program

  1. CKD-339phase 1

Their studies: Chong Kun Dang Pharmaceutical’s studies of Hypertension in search

Ovarian Neoplasmsboth · compare here

Novartis in Ovarian Neoplasms: 1 program

  1. Alpelisibapproved, new study

Their studies: Novartis’s studies of Ovarian Neoplasms in search

Chong Kun Dang Pharmaceutical in Ovarian Neoplasms: 2 programs

  1. CKD-215phase 1
  2. D215phase 1

Their studies: Chong Kun Dang Pharmaceutical’s studies of Ovarian Neoplasms in search

Renal Insufficiencyboth · compare here

Novartis in Renal Insufficiency: 2 programs

  1. PKN605phase 2
  2. asciminibapproved, new study

Their studies: Novartis’s studies of Renal Insufficiency in search

Chong Kun Dang Pharmaceutical in Renal Insufficiency: 1 program

  1. lobeglitazonephase 3

Their studies: Chong Kun Dang Pharmaceutical’s studies of Renal Insufficiency in search

Renal Insufficiency, Chronicboth · compare here

Novartis in Renal Insufficiency, Chronic: 2 programs

  1. Atrasentanphase 3
  2. OJR520phase 1

Their studies: Novartis’s studies of Renal Insufficiency, Chronic in search

Chong Kun Dang Pharmaceutical in Renal Insufficiency, Chronic: 1 program

  1. empagliflozinapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Renal Insufficiency, Chronic in search

Carcinoma, Renal Cellboth · compare here

Novartis in Carcinoma, Renal Cell: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Carcinoma, Renal Cell in search

Chong Kun Dang Pharmaceutical in Carcinoma, Renal Cell: 1 program

  1. Everolimusapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Carcinoma, Renal Cell in search

Heart Failureboth · compare here

Novartis in Heart Failure: 1 program

  1. HJB647phase 1

Their studies: Novartis’s studies of Heart Failure in search

Chong Kun Dang Pharmaceutical in Heart Failure: 1 program

  1. empagliflozinapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Heart Failure in search

Neuroendocrine Tumorsboth · compare here

Novartis in Neuroendocrine Tumors: 1 program

  1. Lutetium-177phase 2

Their studies: Novartis’s studies of Neuroendocrine Tumors in search

Chong Kun Dang Pharmaceutical in Neuroendocrine Tumors: 1 program

  1. Everolimusapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Neuroendocrine Tumors in search

Psoriasisboth · compare here

Novartis in Psoriasis: 1 program

  1. secukinumabapproved, new study

Their studies: Novartis’s studies of Psoriasis in search

Chong Kun Dang Pharmaceutical in Psoriasis: 1 program

  1. CKD-704phase 1

Their studies: Chong Kun Dang Pharmaceutical’s studies of Psoriasis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Novartis 56 of 77 · Chong Kun Dang Pharmaceutical 3 of 18 programs (19 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Novartis: 7).